)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Inhibikase Therapeutics
Inhibikase Therapeutics (IKT) investor relations material
Inhibikase Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
IMPROVE-PAH, the pivotal global Phase 3 study of IKT-001 for PAH, had approvals in 28 countries and 79 of 180 planned sites activated; an interim Part A safety readout in 50 patients is planned for H1 2027.
FDA granted IKT-001 Orphan Drug Designation in July 2026, potentially providing clinical-trial tax credits, fee exemptions and seven years of market exclusivity upon approval.
Financial highlights
Q3 2026 net loss was $20.5M, or $0.10/share, vs. $11.9M, or $0.13/share, in Q3 2025; 9M net loss was $56.4M, or $0.31/share, vs. $35.5M, or $0.40/share.
Q3 R&D expense rose to $15.0M from $7.6M; 9M R&D was $39.2M vs. $23.4M, with 2025 including a $7.4M noncash IPR&D write-off and $1.8M CorHepta-related stock compensation.
Q3 SG&A was $7.2M vs. $5.6M; 9M SG&A was $22.3M vs. $16.8M. Higher stock-based compensation and personnel costs contributed to the increase; 2025 included $1.0M in severance for former senior executives.
Other income was $1.8M in Q3 and $4.7M for 9M, driven by interest on cash, cash equivalents and marketable securities.
Outlook and guidance
Existing cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months after the report date; funding through Part B topline data assumes full, timely exercise of outstanding Series A and B warrants and projected development timelines.
Part A plans ~140 patients, with change in PVR at Week 24 as the primary endpoint; Part B plans ~346 patients, with change in 6MWD at Week 24 as the primary endpoint, and is to begin after Part A's last patient enrolls.
R&D expense is expected to rise for several years as IKT-001 advances and regulatory approval is pursued; substantial additional funding is anticipated. Estimated remaining CRO and CMO contract costs were $107.6M and $8.7M, primarily through 2030.
Nonclinical results for sotatercept combination studies are expected progressively from Q1 2027; Group 2 studies during 2027 and Group 3 studies in late 2027 or early 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Inhibikase Therapeutics
- IKT-001 pairs imatinib’s PAH efficacy potential with a redesigned Phase 3 program.IKT
Corporate presentation - IKT-001 targets PAH with strong efficacy, improved tolerability, and global Phase 3 enrollment underway.IKTCorporate presentation
- IKT-001 targets PAH with improved tolerability and efficacy; Phase 3 topline data expected 2029.IKTCorporate presentation
- Phase 3 PAH trial advances, Orphan Drug Designation secured, and $50M raised in July 2026.IKTQ2 2026
- Q1 2026 net loss reached $16.4M as global Phase 3 PAH trial enrollment and spending increased.IKTQ1 2026
- Director elections, auditor ratification, and equity plan amendments headline the annual meeting.IKTProxy filing
- Virtual annual meeting to vote on directors, auditor, equity plan, and executive pay proposals.IKTProxy filing
- Virtual meeting to vote on directors, auditor, equity plan, and executive compensation matters.IKTProxy filing
- IKT-001 targets PAH with improved tolerability and efficacy, aiming for first-in-class oral approval.IKTCorporate presentation
Next Inhibikase Therapeutics earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
Inhibikase Therapeutics
Next Inhibikase Therapeutics earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.